이상반응 보고
| VAERS ID | 2003100 |
|---|---|
| 성별 | 남성 |
| 나이 | 97세 |
| 주 코드 | FR |
| 제약회사 | PFIZER\BIONTECH |
| 로트 번호 | |
| 예방접종 횟수 | 2 |
| 접종일 | 2021-06-07 |
| 발병일 | 2021-11-24 |
| 상태 | 입원 사망 |
증상
- 기침(Cough)
- SARS-CoV-2 테스트(SARS-CoV-2 test)
- 컴퓨터 단층 촬영 흉부(Computerised tomogram thorax)
- 코로나19 폐렴(COVID-19 pneumonia)
- 저산소증(Hypoxia)
- 약물 효과 없음(Drug ineffective)
- 의심되는 COVID-19(Suspected COVID-19)
이환 중 질병
Arterial hypertension; Atrial fibrillation; Cerebral amyloid angiopathy; Cognitive disorder; Deglutition disorder (swallowing disorders); Depression
지병
기타 의료
BELOC ZOK; SERTRALINE; ELIQUIS; LAXOBERON; QUETIAPINE; TORASEMIDE; DAFALGAN; PURSANA
이전 예방접종
알레르기
임상 검사
Test Date: 20211124; Test Name: thoracic CT scan; Result Unstructured Data: Test Result:shows ground glass infiltrates consistent; Comments: with Covid-19; Test Date: 20211124; Test Name: 10084354; Result Unstructured Data: Test Result:Negative
증상 상세
severe bilateral pneumonia with probable SARS-CoV-2; COVID-19 compatible ground glass infiltrates, Comirnaty vaccine on 26 April 2021 and the second dose on 7 June 2021.
; Despite a negative SARS-CoV-2 test at entry, a chest CT scan shows ground glass infiltrates consistent with COVID-19; desaturation; wet cough and clear sputum; This is a spontaneous report received from a contactable reporter(s) (Physician) from Regulatory Authority.
Regulatory number: CH-SM-2021-29619.
A 97-year-old male patient received bnt162b2 (COMIRNATY), intramuscular, administration date 07Jun2021 (Batch/Lot number: unknown) at the age of 97 years as dose 2, single and intramuscular, administration date 26Apr2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation.
Relevant medical history included: "Atrial fibrillation" (ongoing); "Cerebral amyloid angiopathy" (ongoing); "deglutition disorder" (ongoing), notes: swallowing disorders; "Arterial hypertension" (ongoing); "probably severe cognitive disorder" (ongoing); "Depression" (ongoing).
Concomitant medication(s) included: BELOC ZOK; SERTRALINE; ELIQUIS; LAXOBERON; QUETIAPINE; TORASEMIDE; DAFALGAN; PURSANA.
The following information was reported: DRUG INEFFECTIVE (death, hospitalization, medically significant) with onset 24Nov2021, outcome "fatal", described as "COVID-19 compatible ground glass infiltrates, Comirnaty vaccine on 26 April 2021 and the second dose on 7 June 2021.
"; SUSPECTED COVID-19 (death, hospitalization, medically significant) with onset 24Nov2021, outcome "fatal", described as "Despite a negative SARS-CoV-2 test at entry, a chest CT scan shows ground glass infiltrates consistent with COVID-19"; HYPOXIA (hospitalization, medically significant) with onset 24Nov2021, outcome "not recovered", described as "desaturation"; COUGH (hospitalization, medically significant) with onset 24Nov2021, outcome "not recovered", described as "wet cough and clear sputum"; COVID-19 PNEUMONIA (hospitalization, medically significant), outcome "not recovered", described as "severe bilateral pneumonia with probable SARS-CoV-2".
The patient was hospitalized for drug ineffective, suspected covid-19, hypoxia, cough, covid-19 pneumonia (start date: 24Nov2021).
He was hospitalized on 24Nov2021 for desaturation with a wet cough and clear sputum.
Antibiotic therapy with piperacillin and tazobactam was started.
Despite a negative SARS-CoV-2 test on entry, a chest CT scan showed ground glass infiltrates consistent with COVID-19 according to the physicians.
In addition to oxygen, he was also receiving dexamethasone.
Due to his deteriorating condition, after comfort care was initiated in agreement with the family.
The patient underwent the following laboratory tests and procedures: computerised tomogram thorax: (24Nov2021) shows ground glass infiltrates consistent, notes: with Covid-19; sars-cov-2 test: (24Nov2021) negative.
Therapeutic measures were taken as a result of drug ineffective, suspected covid-19, hypoxia, cough, covid-19 pneumonia.
As per regulatory authority, patient developed severe bilateral pneumonia with probable SARS-CoV-2 6 months after the second injection of COVID-19 vaccine Comirnaty.
The patient date of death was 01Dec2021.
The reported cause of death was suspected covid-19, drug ineffective.
No autopsy was performed.
A causal relationship between Comirnaty and events "Suspected SARS-CoV-2 infection", "Vaccination failure", "Cough" and "Hypoxia" was assessed by the regulatory authority according to WHO method as being Possible.
Regulatory Authority assessed this case as serious with seriousness criteria "results in death", "caused/prolonged hospitalization" and "Other medically important condition".
No follow-up attempts are possible; information about lot/batch number cannot be obtained.
No further information is expected.
; Reported Cause(s) of Death: Suspected SARS-CoV-2 infection; Suspected SARS-CoV-2 infection